Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan · Delayed Price · Currency is TWD 24.25
+0.05 (0.21%)
Oct 16, 2026, 1:30 PM CST
Orient Pharma Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,894 | 5,832 | 8,029 | 4,461 | 3,908 | 3,497 | |
Market Cap Growth | -3.38% | -27.36% | 80.00% | 14.13% | 11.77% | 28.52% |
Enterprise Value | 5,498 | 5,488 | 8,510 | 5,080 | 4,148 | 3,763 |
Last Close Price | 24.25 | 26.15 | 36.00 | 20.00 | 20.90 | 18.70 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.78 | 27.98 | 74.78 | 200.14 | - | - |
PS Ratio | 3.89 | 4.17 | 6.57 | 5.01 | 7.64 | 7.55 |
PB Ratio | 2.22 | 2.28 | 4.49 | 2.67 | 3.59 | 3.13 |
P/TBV Ratio | 2.59 | 2.71 | 6.10 | 3.92 | 3.63 | 3.17 |
P/FCF Ratio | 29.16 | 18.00 | 47.69 | - | - | - |
P/OCF Ratio | 20.20 | 16.21 | 41.03 | - | 343.32 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.63 | 3.92 | 6.96 | 5.71 | 8.10 | 8.12 |
EV/EBITDA Ratio | 13.32 | 14.61 | 31.21 | 36.55 | 333.67 | - |
EV/EBIT Ratio | 19.65 | 21.02 | 53.89 | 208.88 | - | - |
EV/FCF Ratio | 27.20 | 16.94 | 50.54 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.07 | 0.08 | 0.31 | 0.43 | 0.47 | 0.37 |
Debt / EBITDA Ratio | 0.46 | 0.50 | 1.87 | 4.52 | 20.74 | - |
Debt / FCF Ratio | 0.94 | 0.61 | 3.25 | - | - | - |
Net Debt / Equity Ratio | -0.15 | -0.17 | 0.25 | 0.36 | 0.38 | 0.24 |
Net Debt / EBITDA Ratio | -1.00 | -1.15 | 1.60 | 4.35 | 33.06 | -3.20 |
Net Debt / FCF Ratio | -1.96 | -1.33 | 2.60 | -3.84 | -24.15 | -2.19 |
Asset Turnover | 0.55 | 0.51 | 0.48 | 0.40 | 0.28 | 0.26 |
Inventory Turnover | 2.03 | 2.03 | 2.23 | 1.97 | 2.03 | 2.17 |
Quick Ratio | 5.06 | 4.77 | 0.82 | 0.53 | 0.51 | 0.55 |
Current Ratio | 7.39 | 6.73 | 1.50 | 1.11 | 1.21 | 1.05 |
Return on Equity (ROE) | 10.42% | 9.58% | 6.21% | 1.62% | -2.61% | -8.80% |
Return on Assets (ROA) | 6.29% | 5.98% | 3.88% | 0.69% | -1.44% | -4.76% |
Return on Invested Capital (ROIC) | 10.46% | 10.21% | 4.62% | 1.25% | -2.90% | -9.78% |
Return on Capital Employed (ROCE) | 9.90% | 9.50% | 7.80% | 1.20% | -2.80% | -9.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.99% | 3.57% | 1.34% | 0.50% | -0.74% | -2.94% |
FCF Yield | 3.43% | 5.56% | 2.10% | -3.52% | -0.43% | -3.43% |
Buyback Yield / Dilution | -7.81% | -3.32% | - | -19.27% | 0.00% | -10.40% |